Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2485539 | Journal of Pharmaceutical Sciences | 2008 | 9 Pages |
Abstract
In vivo pharmacokinetic and brain binding characteristics of (+)-[11C]A-69024, a high-affinity-D1-selective dopamine receptor antagonist, were assessed with micro-PET and β-microprobes in the rat and PET in the baboon. The biodistribution of (+)-[11C]A-69024 in rats and baboons showed a rapid brain uptake (reaching a maximal value at 5 and 15 min postinjection in rats and baboons, respectively), followed by a slow wash out. The region/cerebellum concentration ratio was characterized by a fourfold higher uptake in striatum and a twofold higher uptake in cortical regions, consistent with in vivo specific binding of the radiotracer in these cerebral regions. Furthermore, this specific (+)-[11C]A-69024 binding significantly correlated with the reported in vitro distribution of dopamine D1-receptors. Finally, the specific uptake of the tracer in the striatum and cortical regions was completely prevented by either a pretreatment with large doses of nonradioactive (±)A-69024 or of the D1-selective antagonist SCH23390, resulting in a similar uptake in the reference region (cerebellum) and in other brain regions. Thus, (+)-[11C]A-69024 appears to be a specific and enantioselective radioligand to visualize and quantify brain dopamine D1 receptors in vivo using positron emission tomography.
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Drug Discovery
Authors
Laurent Besret, Frédéric Dollé, Anne-Sophie Hérard, Martine Guillermier, Stéphane Demphel, Françoise Hinnen, Christine Coulon, Michèle Ottaviani, Michel Bottlaender, Philippe Hantraye, Michael Kassiou,